Nephrologists Agree That There is a High Unmet Need for an Effective Treatment ... MarketWatch (press release) The highest awareness was associated with Otsuka's Samsca(R) (tolvaptan) and irolimus/rapamycin. Physicians also had some familiarity with the potential use of mTOR inhibitors, Astellas's tacrolimus or Novartis's everolimus, for this disease state. |
